Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China
Nov 1, 2016, 00:00
10.1016/j.jval.2016.08.212
https://www.valueinhealthjournal.com/article/S1098-3015(16)30792-6/fulltext
Title :
Cost-Effectiveness of Dapagliflozin Versus Acarbose as A Monotherapy in Type 2 Diabetes in China
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30792-6&doi=10.1016/j.jval.2016.08.212
First page :
A898
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2787